

Pharmacy Program Updates: Quarterly Pharmacy Changes Effective April 1, 2020 – Part 2

This article is a continuation of the previously published *Quarterly Pharmacy Changes Part 1 article*. While that part 1 article included the drug list revisions/exclusions, dispensing limits, utilization management changes and general information on pharmacy benefit program updates, this part 2 version contains the more recent coverage additions, utilization management updates and any other updates to the pharmacy program.

DRUG LIST CHANGES

Based on the availability of new prescription medications and Prime's National Pharmacy and Therapeutics Committee's review of changes in the pharmaceuticals market, some additions (new to coverage) and/or some coverage tier changes (drugs moved to a lower out-of-pocket payment level) will be made to the Blue Cross and Blue Shield of Texas (BCBSTX) drug lists.

Please note: Revisions (drugs still covered but moved to a higher out-of-pocket payment level) and/or exclusions (drugs no longer covered) were included in the *Quarterly Pharmacy Changes Part 1 article*. Your patient(s) may ask you about therapeutic or lower cost alternatives if their medication is affected by one of these changes.

Changes effective April 1, 2020 are outlined below.

Drug List Coverage Additions - As of April 1, 2020

Preferred Drug ¹	Drug Class/Condition Used For	
Basic, Basic Annual, Multi-Tier Basic, Multi-Tier Basi	c Annual, Enhanced, Enhanced Annual,	
Multi-Tier Enhanced and Multi-Tier Enhanced Annual Drug Lists		
DIVIGEL (estradiol td gel 1.25 mg/1.25 gm (0.1%))	Hot Flashes	
GVOKE PFS (glucagon subcutaneous soln pref syringe	Diabetes	
0.5 mg/0.1 ml, 1 mg/0.2 ml)		
HARVONI (ledipasvir-sofosbuvir tab 45-200 mg)	Hepatitis C	
INSULIN ASPART (insulin aspart inj 100 unit/ml)	Diabetes	
INSULIN ASPART FLEXPEN (insulin aspart soln pen-	Diabetes	
injector 100 unit/ml)		
INSULIN ASPART PENFILL (insulin aspart soln cartridge	Diabetes	
100 unit/ml)		
INSULIN ASPART PROTAMINE/INSULIN ASPART	Diabetes	
(insulin aspart prot & aspart (human) inj 100 unit/ml (70-		
30))		
INSULIN ASPART PROTAMINE/INSULIN ASPART	Diabetes	
FLEXPEN (insulin aspart prot & aspart sus pen-inj 100		
unit/ml (70-30))		
LYNPARZA (olaparib cap 50 mg; tab 100 mg, 150 mg)	Cancer	
NOVOLIN N FLEXPEN (insulin nph (human) (isophane)	Diabetes	
susp pen-injector 100 unit/ml)		
NOVOLIN R FLEXPEN (insulin regular (human) soln	Diabetes	
pen-injector 100 unit/ml)		
NUBEQA (darolutamide tab 300 mg)	Cancer	
ROZLYTREK (entrectinib cap 100 mg, 200 mg)	Cancer	
RUBRACA (rucaparib camsylate tab 200 mg, 250 mg,	Cancer	
300 mg (base equivalent))		
RYBELSUS (semaglutide tab 3 mg, 7 mg, 14 mg)	Diabetes	

A Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association



SOVALDI (sofosbuvir tab 200 mg)	Hepatitis C
TEMIXYS (lamivudine-tenofovir disoproxil fumarate tab	Infections
300-300 mg)	IIIIections
TRIFLURIDINE (trifluridine ophth soln 1%)	Ophthalmic Infections
TRIKAFTA (elexacaf-tezacaf-ivacaf 100-50-75 mg &	Cystic Fibrosis
·	Cystic Fibrosis
ivacaftor 150 mg tbpk)	
Polonced Performance Performance Annual o	nd Dorformanae Calact Drug Liete
Balanced, Performance, Performance Annual a COMPACT SPACE CHAMBER/ANTI-STATIC/SMALL	
	Spacer for Inhaler
MASK (spacer/aerosol-holding chambers - device) COMPACT SPACE CHAMBER/ANTI-STATIC/MEDIUM	Spacer for Inhaler
	Spacer for infraler
MASK (spacer/aerosol-holding chambers - device) COMPACT SPACE CHAMBER/ANTI-STATIC/LARGE	Chasarfarlabalar
	Spacer for Inhaler
MASK (spacer/aerosol-holding chambers - device)	Object in the conference of
deferasirox tab 90 mg, 360 mg (generic for JADENU)	Chronic Iron Overload
DEXCOM G5 MOBILE RECEIVER KIT (continuous blood	Diabetes/Continuous Blood Glucose
glucose system receiver)	Monitoring
DEXCOM G5 MOBILE TRANSMITTER KIT (continuous	Diabetes/Continuous Blood Glucose
blood glucose system transmitter)	Monitoring
DEXCOM G5 MOBILE/G4 PLATINUM SENSOR KIT	Diabetes/Continuous Blood Glucose
(continuous blood glucose system sensor)	Monitoring
DEXCOM G6 RECEIVER (continuous blood glucose	Diabetes/Continuous Blood Glucose
system receiver)	Monitoring
DEXCOM G6 SENSOR (continuous blood glucose	Diabetes/Continuous Blood Glucose
system sensor)	Monitoring
DEXCOM G6 TRANSMITTER (continuous blood glucose	Diabetes/Continuous Blood Glucose
system transmitter)	Monitoring
DEXCOM RECEIVER KIT (continuous blood glucose	Diabetes/Continuous Blood Glucose
system receiver)	Monitoring
digoxin oral soln 0.05 mg/ml (generic for DIGOXIN)	Heart Failure, Atrial Fibrillation
FASENRA PEN (benralizumab subcutaneous soln auto-	Asthma
injector 30 mg/ml)	
FIASP PENFILL (insulin aspart (with niacinamide) soln	Diabetes
cartridge 100 unit/ml)	
GVOKE PFS (glucagon subcutaneous soln pref syringe	Diabetes
0.5 mg/0.1 ml, 1 mg/0.2 ml)	
HARVONI (ledipasvir-sofosbuvir tab 45-200 mg)	Hepatitis C
HEPARIN SODIUM (heparin sodium (porcine) pf inj 5000	Clotting Conditions
unit/ml)	
INREBIC (fedratinib hcl cap 100 mg)	Cancer
mesalamine cap er 24hr 0.375 gm (generic for APRISO)	Ulcerative Colitis
NAYZILAM (midazolam nasal spray soln 5 mg/0.1 ml)	Seizures
nitisinone cap 2 mg, 5 mg, 10 mg (generic for ORFADIN)	Hereditary Tyrosinemia Type 1 (HT-1)
NUBEQA (darolutamide tab 300 mg)	Cancer
OXYMORPHONE HYDROCHLORIDE ER (oxymorphone	Pain
hcl tab er 12hr 15 mg)	
pentamidine isethionate for nebulization soln 300 mg	Fungal Infections
(generic for NEBUPENT)	
PREDNISOLONE SODIUM PHOSPHATE (prednisolone	Inflammatory Conditions
sodium phosphate oral soln 25 mg/5 ml (base eq))	
ROZLYTREK (entrectinib cap 100 mg, 200 mg)	Cancer
RYBELSUS (semaglutide tab 3 mg, 7 mg, 14 mg)	Diabetes
SOVALDI (sofosbuvir tab 200 mg)	Hepatitis C
, ,,	



TEMIXYS (lamivudine-tenofovir disoproxil fumarate	tab	Infections
300-300 mg)		
TRIKAFTA (elexacaf-tezacaf-ivacaf 100-50-75 mg &	<u>k</u>	Cystic Fibrosis
ivacaftor 150 mg tbpk)		
TURALIO (pexidartinib hcl cap 200 mg (base equiva	alent))	Cancer
VYLEESI (bremelanotide acetate subcutaneous sol	VYLEESI (bremelanotide acetate subcutaneous soln	
auto-injector 1.75 mg/0.3 ml)*		
Balanced Drug List		
ASPIRIN/OMEPRAZOLE (aspirin-omeprazole tab	Myoca	ardial Infarction and Stroke Prophylaxis
delayed release 81-40 mg)		
CIPROFLOXACIN/FLUOCINOLONE	Otic Ir	nfections & Inflammation
ACETONIDE PF (ciprofloxacin-fluocinolone		
aceton (pf) otic soln 0.3-0.025%)		
CLOCORTOLONE PIVALATE (clocortolone	Inflam	nmatory Conditions
pivalate cream 0.1%)		1 0 10
CLODERM (clocortolone pivalate cream 0.1%)		matory Conditions
DRIZALMA SPRINKLE (duloxetine hcl cap	Major	Depressive Disorder
delayed release sprinkle 20 mg, 30 mg, 40 mg, 60		
mg (base eq))	Inflan	amatam. Canditiana
· ·		nmatory Conditions
propionate foam 0.05%) NEONATAL COMPLETE (prenatal vit w/ fe	Dropo	ıtal Vitamin
fumarate-fa tab 27-1 mg)	Prena	itai vitaiiiii
NOURIANZ (istradefylline tab 20 mg, 40 mg)	Darkir	nson's Disease
OZOBAX (baclofen oral soln 5 mg/5 ml)		le Sclerosis
PREGENNA (prenat vit w/ fe bisglyc chelate-fa		Ital Vitamin
tab 20-1 mg (1.7 mg dfe))	Fiella	itai vitaiiiii
sucralfate susp 1 gm/10 ml (generic for	Ulcers	2
CARAFATE susp)	Olocia	
TOSYMRA (sumatriptan nasal spray 10 mg/act)	Migra	ines
VITATHELY/GINGER (prenatal vit w/ fe fumarate-		Ital Vitamin
fa tab 27-1 mg)		
ZALVIT (prenatal vit w/ fe gluconate-fa tab 13-1	Prena	ital Vitamin
mg)		
<u> </u>	L	

Drug List Updates (Coverage Tier Changes) – As of April 1, 2020

Drug ¹	New Lower Tier	Drug Class/Condition Used For
Balanced, Performance, Performance Annual and Performance Select Drug Lists		
bromfenac sodium ophth soln 0.09%	Non-Preferred Generic	Cataracts, Inflammatory
(base equiv) (once-daily)		Conditions
metoprolol tartrate tab 37.5 mg, 75 mg	Non-Preferred Generic	Hypertension
prednisone tab 50 mg	Non-Preferred Generic	Inflammatory Conditions
RUBRACA (rucaparib camsylate tab 200	Preferred Brand	Cancer
mg, 250 mg, 300 mg (base equivalent))		
SYNTHROID (levothyroxine sodium tab	Preferred Brand	Hypothyroidism
25 mcg, 50 mcg, 75 mcg, 88 mcg, 100		
mcg, 112 mcg, 125 mcg, 137 mcg, 150		
mcg, 175 mcg, 200 mcg, 300 mcg)		

¹Third-party brand names are the property of their respective owner.

* Optional sexual dysfunction component coverage for select health plans.




Balanced Drug List		
triamcinolone acetonide oint 0.05%	Non-Preferred Generic	Inflammatory Conditions

DISPENSING LIMIT CHANGES

The BCBSTX prescription drug benefit program includes coverage limits on certain medications and drug categories. Dispensing limits are based on U.S. Food and Drug Administration (FDA) approved dosage regimens and product labeling. **Changes by drug list are listed on the charts below. Please note:** The dispensing limits listed below only apply to select members whose plan has moved to quarterly updates on their prescription drug list. BCBSTX members on an annually updated prescription drug list will have these dispensing limits applied on or after Jan. 1, 2021, unless stated otherwise.

Effective April 1, 2020:

Drug Class and Medication(s) ¹	Dispensing Limit(s)		
Basic, Basic Annual, Enhanced, Enhanced	Annual, Balanced, Performance, Performance		
Annual and Performa	Annual and Performance Select Drug Lists		
5HT-1F			
Reyvow 5 mg	4 tablets per 30 days		
Reyvow 10 mg	8 tablets per 30 days		
	ormance Annual, Performance Select Drug Lists		
Continuous Glucose Monitors			
Dexcom G5 Transmitter	1 transmitter per 84 days		
Dexcom G5/G4 Sensor	4 sensors per 28 days		
Dexcom G5 Receiver	1 receiver per 365 days		
Dexcom G6 Transmitter	1 transmitter per 90 days		
Dexcom G6 Sensor	3 sensors per 30 days		
Dexcom G6 Receiver	1 receiver per 365 days		
Dexcom G4 Platinum Sensor	4 sensors per 28 days		
Dexcom G4 Platinum Transmitter	1 transmitter per 90 days		
Dexcom G4 Platinum Receiver	1 receiver per 365 days		
Eversense Sensor	1 sensor per 90 days		
Eversense Transmitter	1 transmitter per 90 days		
Freestyle Libre Sensor - 10 day	3 sensors per 30 days		
Freestyle Libre Reader - 10 day	1 reader per 365 days		
Freestyle Libre Sensor - 14 day	2 sensors per 28 days		
Freestyle Libre Reader - 14 day	1 reader per 365 days		
Guardian Sensor	4 sensors per 28 days		
Guardian Transmitter	1 transmitter per 90 days		
Guardian Kit	1 kit per 365 days		
Balanced, Performance, Performance Annual and Performance Select Drug Lists			
Nasal Antiepileptics			
Nayzilam	10 sprays per 30 days		
Valtoco 5 mg	10 packs per 30 days		
Valtoco 10 mg	10 packs per 30 days		
Valtoco 15 mg	10 packs per 30 days		
Valtoco 20 mg	10 packs per 30 days		



Wakix	
Wakix 4.45 mg	60 tablets per 30 days
Wakix 17.8 mg	60 tablets per 30 days

¹Third-party brand names are the property of their respective owner.

UTILIZATION MANAGEMENT PROGRAM CHANGES

- Effective April 1, 2020, the following changes will be applied:
 - The Wakix Specialty Prior Authorization (PA) program will be added to the Balanced, Performance, Performance Annual and Performance Select Drug Lists. This program includes the target drug Wakix.
 - The 5HT-1F PA program will be added for standard pharmacy benefit plans and all prescription drug lists. This program includes the newly FDA-approved target drug Reyvow.
 - The Continuous Glucose Monitor PA program will be added to the Basic, Basic Annual, Enhanced, Enhanced Annual, Balanced, Performance, Performance Annual and Performance Select Drug Lists. The program includes the following products: Dexcom G4 Platinum CGM System, Dexcom G5 Mobile CGM System, Dexcom G6 CGM System, Freestyle Libre, Guardian Real-Time CGM System and Senseonics Eversense. Members with a recent claim for any of these products will be grandfathered from participation.

For the most up-to-date drug list and list of drug dispensing limits, visit the Pharmacy Program section of our Provider website.

If your patients have any questions about their pharmacy benefits, please advise them to contact the number on their member ID card. Members may also visit *bcbstx.com* and log in to Blue Access for MembersSM (BAMSM) or MyPrime.com for a variety of online resources.


Reminder: Drug Coupon Change

Drug manufacturer coupons (or copay cards) used by members for specialty and non-specialty drugs will not count toward the deductible (if applicable) and/or annual out-of-pocket maximum effective on or after Jan. 1, 2020. This change applies to most BCBSTX members with a group health plan, though some exceptions may apply.

Letters were sent in January to members who have plans renewing in Q2 2020 and have been identified as using a drug coupon. Please call the number on the member's ID card to verify coverage, or for further assistance or clarification on your patient's benefits.

Dexcom Continuous Glucose Monitoring Products Added to Select Drug Lists

On April 1, 2020, brand Dexcom continuous glucose monitoring products will be added to the Balanced, Performance, Performance Annual, Performance Select and Health Insurance Marketplace Drug Lists. These products may have previously been covered only under the member's medical benefit plan. These products may be targeted by the Continuous Glucose Monitors PAQL Program effective April 1, 2020.



Prime Therapeutics LLC is a pharmacy benefit management company. BCBSTX contracts with Prime to provide pharmacy benefit management and related other services. BCBSTX, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime. MyPrime.com is an online resource offered by Prime Therapeutics.

The information mentioned here is for informational purposes only and is not a substitute for the independent medical judgment of a physician. Physicians are to exercise their own medical judgment. Pharmacy benefits and limits are subject to the terms set forth in the member's certificate of coverage which may vary from the limits set forth above. The listing of any particular drug or classification of drugs is not a guarantee of benefits. Members should refer to their certificate of coverage for more details, including benefits, limitations and exclusions. Regardless of benefits, the final decision about any medication is between the member and their health care provider.